High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer.
breast cancer
cyclin D1
immunohistochemistry
prognosis
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
03
2021
accepted:
09
04
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
The cyclin D1 protein regulates cell cycle progression which is mediated by its interactions with cyclin-dependent kinases. Over-expression of cyclin D1 has been observed in several human cancers. This study was conducted to evaluate cyclin D1 expression in a large cohort of Middle Eastern breast cancers and determine its prognostic significance. Cyclin D1 expression was assessed immunohistochemically and its association with clinico-pathological parameters was analyzed in 1003 breast cancer patients. Cyclin D1 was over-expressed in 59.4% (596/1003) of cases and significantly associated with a subset of breast cancers having favorable prognostic features, such as low grade (p < 0.0001), low stage (p = 0.0276), estrogen receptor (p < 0.0001) and progesterone receptor positive (p < 0.0001) tumors. An inverse association was found with triple negative breast cancers (p < 0.0001). More importantly, cyclin D1 expression was an independent predictor of favorable overall survival in our cohort (hazard ratio = 0.70; 95% confidence interval = 0.50-0.98; p = 0.0395). Also, tumors that highly expressed cyclin D1 had a longer recurrence-free survival. However, this significant association was seen only in univariate analysis. We also found cyclin D1 to be associated with phospho-Rb in luminal subtype of breast cancer and co-expression of both these markers was an independent predictor of luminal A breast cancer. Our results reinforced the role of cyclin D1 in breast cancer pathology and revealed its expression as a valuable independent prognostic indicator for breast cancer from Middle Eastern ethnicity.
Identifiants
pubmed: 34040395
doi: 10.2147/OTT.S309091
pii: 309091
pmc: PMC8141388
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3309-3318Informations de copyright
© 2021 Siraj et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest for this work.
Références
Cell. 2000 Mar 31;101(1):79-89
pubmed: 10778858
Breast Cancer Res. 2015 Sep 17;17:127
pubmed: 26384210
Sign Transduct Insights. 2015;4:1-13
pubmed: 28090171
Nat Rev Cancer. 2007 Oct;7(10):791-9
pubmed: 17851544
ESMO Open. 2019 May 12;4(2):e000441
pubmed: 31231556
Cell. 1997 Feb 7;88(3):405-15
pubmed: 9039267
Mod Pathol. 2005 Jul;18(7):891-7
pubmed: 15803183
Breast Cancer Res Treat. 2017 Aug;164(3):667-678
pubmed: 28528450
Breast Cancer Res. 2012 Apr 04;14(2):R57
pubmed: 22475046
Histopathology. 2013 Feb;62(3):472-80
pubmed: 23163571
Breast Cancer. 2016 Jan;23(1):111-119
pubmed: 24862872
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Breast Cancer. 2014 Mar;17(1):47-53
pubmed: 24744797
Front Biosci (Schol Ed). 2012 Jan 01;4:831-9
pubmed: 22202094
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1708-18
pubmed: 16985034
BMC Cancer. 2010 May 21;10:223
pubmed: 20492711
Genes Dev. 1999 Jun 15;13(12):1501-12
pubmed: 10385618
Elife. 2014 Jun 04;3:
pubmed: 24876129
Breast Cancer Res. 2013 Jan 21;15(1):R5
pubmed: 23336272
Clin Cancer Res. 2008 Mar 15;14(6):1767-74
pubmed: 18347178
Am J Pathol. 2013 Jul;183(1):3-9
pubmed: 23790801
Oncotarget. 2017 Dec 16;9(3):3590-3604
pubmed: 29423068
Br J Cancer. 2017 Sep 5;117(6):856-866
pubmed: 28751758
Cancer Res. 2004 Dec 1;64(23):8534-40
pubmed: 15574759
Mol Cell. 2019 May 16;74(4):758-770.e4
pubmed: 30982746
J Cell Physiol. 2009 Aug;220(2):292-6
pubmed: 19415697
Anticancer Res. 2017 Jun;37(6):2947-2957
pubmed: 28551632
Exp Mol Pathol. 2013 Feb;94(1):73-8
pubmed: 23031786
PLoS One. 2017 Nov 15;12(11):e0188068
pubmed: 29140993
Arch Med Res. 2007 Nov;38(8):846-52
pubmed: 17923265
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Pathol Int. 2003 Feb;53(2):74-80
pubmed: 12588434
Breast Cancer Res Treat. 2008 May;109(2):325-35
pubmed: 17653856
BJU Int. 2017 May;119(5):741-747
pubmed: 28075543
PLoS One. 2014 Apr 11;9(4):e94508
pubmed: 24728073
Oncogenesis. 2021 Mar 1;10(3):21
pubmed: 33649296
J Clin Invest. 2012 Mar;122(3):833-43
pubmed: 22307325
Breast Cancer Res. 2002;4(1):14-7
pubmed: 11879554
Am J Transl Res. 2016 Jan 15;8(1):142-53
pubmed: 27069548
BMC Cancer. 2015 Apr 15;15:285
pubmed: 25879784
Biosci Rep. 2021 Jan 29;41(1):
pubmed: 33438725
Genes Dev. 2006 Sep 15;20(18):2513-26
pubmed: 16980581
Breast Cancer Res Treat. 2013 Jun;139(2):329-39
pubmed: 23670132